KanekaQH(TM) Ubiquinol Dramatically Boosts Ejection Fraction in Patients With Late-Stage Congestive Heart Failure



    Results of first clinical trial indicate pre-converted form of Coenzyme
Q10 positively impacted heart function in critically ill subjects
    

    
    HOUSTON, Feb. 18 /PRNewswire/ -- Results from the first clinical trial
evaluating ubiquinol's effects on late-stage congestive heart failure showed
that the newly available pre-converted form of Coenzyme Q10 (CoQ10)
dramatically boosted ejection fraction in critically ill patients.  Published
in the January 2009 issue of Biofactors, a peer-reviewed scientific journal,
the year-long study showed that patients' ejection fraction (EF), the capacity
at which their heart pumps blood, in some cases more than tripled.
    

    
    Healthy individuals typically have EF levels of 55 to 70 percent.  Damage
to the heart muscle, such as that sustained following a heart attack,
heart-valve problems, or during myocardial infarction or myocardiomyopathy,
impairs the heart's ability to eject blood and therefore reduces EF.
    

    
    All of the patients that participated in this clinical trial had an EF
level below a 35 percent and were classified as New York Heart Association
(NYHA) Class IV - a designation that denotes patients' showed symptoms of
insufficient heart function while at rest and were unable to carry out any
form of physical activity without discomfort.  The prognosis for patients with
NYHA Class IV heart failure is very poor, with mortality rates as high as 74
percent within 6 months and 94 percent within 12 months.
    

    
    From June 2006 through May of 2007, the clinical trial followed seven
Class IV patients who were under maximal medical therapy and supplementing
their treatments with ubiquinone (CoQ10).  The study, led by cardiologist
Peter Langsjoen, assessed the effect of changing their ubiquinone
supplementation to ubiquinol (Kaneka QH(TM)).
    

    
    When switched to supplemental ubiquinol, there was a dramatic increase in
both the patients' EF and plasma CoQ10 levels with corresponding improvements
in clinical status in all seven patients.  The improvements while on ubiquinol
were so significant that six of the seven patients survived longer than
expected and remained stable between NYHA Class I-III for an average of 12
months.
    

    
    "In 25 years of experience in treating congestive heart failure, we have
consistently seen the best response when CoQ10 is begun early in the course of
the disease," said Dr. Langsjoen, who conducted the research in Tyler, Texas.
    

    
    "The improvement in ejection fraction levels in these seven patients with
end-stage congestive heart failure was associated with overall clinical
improvement.  It is likely that ubiquinol would show even more clinical
benefit in early congestive heart failure. Future controlled trials of Kaneka
QH(TM) in congestive heart failure are anxiously awaited."
    

    About Kaneka QH(TM) (ubiquinol)
    
    Both ubiquinone and ubiquinol are essential to generating cellular energy
and sustaining life; however, the reduced form, ubiquinol, is responsible for
the powerful antioxidant benefits associated with CoQ10.  More than 90 percent
of the CoQ10 found in a healthy person's plasma is in its reduced ubiquinol
form.
    

    
    For the past 40 years, only ubiquinone was available as a supplement. 
KanekaQH(TM), the world's only supplemental ubiquinol, has only been available
since late 2006.  The ingredient, manufactured exclusively by Kaneka, is
currently available in more than 30 consumer supplements.
    

    
    "Cardiovascular patients, those fighting age-related diseases and even
healthy people over the age of 40 have a critical need to optimize the EF and
plasma CoQ10 levels within their bodies," explained Dr. Robert Barry of Kaneka
Nutrients, L.P.  "Because it's so much better absorbed by the body,
KanekaQH(TM) can raise CoQ10 levels more effectively and, as we're seeing from
Dr. Langsjoen's study, can have tremendous health impact on those suffering
from debilitating diseases."
    

    
    Full results of Dr. Langsjoen's supplemental ubiquinol study is available
 www.kanekaqh.com/clinicaltrials. More information on supplemental ubiquinol
is available at www.kanekaqh.com.
    

    About Kaneka Nutrients
    
    Kaneka Nutrients L.P. is a wholly-owned subsidiary of Kaneka Corporation
(www.kaneka.co.jp/kaneka-e/), headquartered in Japan.  The company, based in
Pasadena, Texas, manufactures an array of unique nutritional ingredients for
the supplement and food & beverage industries.  Kaneka is the largest
manufacturer of CoQ10 in the world, and the only company that manufactures
CoQ10 in the U.S.
    




    




For further information:

For further information: Tiffany Heikkila, +1-713-752-1923,
Tiffany.Heikkila@hillandknowlton.com, or Jamie Tinsley, +1-712-752-1928,
Jamie.Tinsley@hillandknowlton.com, both of Hill & Knowlton Houston, for Kaneka
Nutrients L.P. Web Site: http://www.kanekaqh.com

Organization Profile

KANEKA NUTRIENTS L.P.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890